Kelley v. Johnson
496 S.W.3d 346
Ark.2016Background
- Eight death-row inmates sued Arkansas Department of Correction (ADC) challenging Act 1096 (Ark. Code Ann. § 5-4-617 (Supp. 2015)), which prescribes lethal-injection options (barbiturate or midazolam/vecuronium/potassium chloride) and makes supplier identities confidential, shielding disclosure absent court-ordered protective relief.
- Plaintiffs previously settled related litigation (Act 139 protocol) with ADC; settlement required disclosure of new protocols and certain drug packaging/labels but did not expressly require ongoing supplier identification across future statutory schemes.
- ADC moved to dismiss and for summary judgment invoking sovereign immunity, arguing plaintiffs failed to plead/prove constitutional violations (method-of-execution and nondisclosure claims). Circuit court denied immunity on many claims and granted plaintiffs partial summary judgment on disclosure claims; ADC appealed interlocutorily.
- Lower courts had testing and affidavits: ADC tested the supplied drugs and produced lab results matching labels; plaintiffs proffered expert affidavits proposing alternative execution methods (firing squad, barbiturate overdose, anesthetic gases, high-dose opioids) with declarations that such alternatives are commercially available and humane.
- ADC submitted affidavits showing suppliers/manufacturers decline to sell execution drugs to corrections departments and that current supplier required anonymity; ADC argued alternatives were not actually available to ADC and thus not "feasible, readily implemented".
- Supreme Court of Arkansas reversed in full: dismissed the inmates’ method-of-execution claims for failure to plead/produce feasible alternatives and reversed circuit-court rulings requiring disclosure of supplier identity (holding confidentiality provisions constitutional under the state constitution and consistent with practical necessity).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether midazolam three‑drug protocol constitutes cruel or unusual punishment under Ark. Const. art. 2 § 9 | Midazolam protocol poses a risk of severe pain; plaintiffs offered alternatives that would significantly reduce risk | Plaintiffs failed to plead/prove feasible, readily implemented alternatives and failed to show protocol causes a "sure or very likely" risk of severe pain | Dismissed: plaintiffs failed second‑prong (feasible, readily implemented alternatives); method‑of‑execution claim dismissed |
| Whether substantive due‑process challenge (art. 2 § 8) overlaps and avoids Glossip/Baze burden | Substance‑due‑process protects against objectively unreasonable risk of pain; need not identify alternatives | Method‑of‑execution claims governed by Eighth‑Amendment‑style test—plaintiffs must meet Glossip/Baze standards | Dismissed: claim subsumed by Eighth‑type test and failed for same reasons |
| Whether Act 1096’s confidentiality provisions violate procedural due process by preventing meaningful challenge | Identities of drug suppliers are necessary for meaningful litigation and access to evidence | Provenance and independent lab testing of ADC’s drugs eliminate need for supplier identity; disclosure would harm state ability to obtain drugs | Reversed: no due‑process right to supplier identity; disclosure not required |
| Whether confidentiality provisions violate free-speech/press (art. 2 § 6) or publication clause (art. 19 § 12) | Public access and tradition justify disclosure; publication clause requires disclosure of public expenditures | Public access would frustrate ADC’s ability to obtain drugs; statute prescribes manner/timing of publication, and publication clause is not self‑executing | Reversed: no First‑Amendment‑style right of access here; publication clause not self‑executing in a way that invalidates Act 1096 |
| Whether Act 1096 impairs the settlement agreement and violates Contract Clause (art. 2 § 17) | Settlement obligated ADC to disclose packaging and supplier info for future protocols | Settlement obligations were limited to the Act 139 context and concluded with that litigation; no continuing supplier‑identification obligation | Reversed: no contractual obligation survives to compel supplier identity; contract‑clause challenge fails |
| Whether interlocutory appeal was proper on sovereign‑immunity grounds | Plaintiffs argued circuit court failed to rule on sovereign immunity | ADC argued circuit court decided grounds raised as basis for immunity in its orders | Court held appeal proper because circuit court ruled on ADC’s immunity contentions |
Key Cases Cited
- Hobbs v. McGehee, 458 S.W.3d 707 (Ark. 2015) (upholding statutory guidance to ADC re: method‑of‑execution; prior separation‑of‑powers analysis)
- Baze v. Rees, 553 U.S. 35 (2008) (Eighth Amendment standard: method must not present risk sure or very likely to cause severe pain)
- Glossip v. Gross, 135 S. Ct. 2726 (2015) (clarified that prisoner must identify a known, feasible, readily implemented alternative that significantly reduces substantial risk)
- Alpha Mktg. v. Ark. Lottery Comm’n, 386 S.W.3d 400 (Ark. 2012) (interlocutory appeal on sovereign immunity requires circuit court ruling on immunity)
- Zink v. Lombardi, 783 F.3d 1089 (8th Cir. 2015) (public disclosure of lethal‑drug suppliers can impede states’ ability to obtain drugs; no right of access to supplier identities)